Opportunistic biotech trading bitch with a focus on nucleic acid-based and -targeted biotech. Fiercely independent. https://t.co/dfLqOuH7Uh
Cite asCryptoQuant has tracked the directional calls on QURE by @RNAiAnalyst on X since Aug 2025: not yet scored on QURE (as of Nov 11, 2026).
Other assets covered (14)
8 QURE calls on record, a thin history.
Relative view by default: fewer than 30 QURE calls or days on record.
Sentiment timeline shows relative sentiment within this analyst's history. A perma-bull showing 8 bullish : 2 bearish in a bear market sets that as their baseline. If you notice any errors, claim @RNAiAnalyst to submit corrections.
Hover the chart to read the thesis of that period · click a day to pin it
$QURE has AMT-130 become a short-the-launch story (similar to $NTLA)? How else to explain suppressed share price despite rapid progress to commercialization.
View original →$QURE nice rugpull. Widely advertized to go up 25%+ on BLA acceptance, then premarket print of +25% and down ever since.
View original →Great 60% htt knockdown at single doses already. Uses intrathecal delivery, so striatal knockdown for this exon1-targeter could be modest and complementary with $QURE's striatal delivery. $ALNY $ARWR https://t.co/zrKtav3zPL
View original →
